| Molecular positron emission tomography and PET/CT imaging in urological malignancies. | |
| | |
MedLine Citation:
|
PMID: 17275167 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: Positron emission tomography (PET) provides unique insights into molecular pathways of diseases. PET using [F-18]-fluorodeoxyglucose (FDG) has gained increasing acceptance for the diagnosis, staging, and treatment monitoring of various tumour types. The aim of this review is to provide an update on the current status of molecular PET and PET/CT imaging in urological malignancies. METHODS: The current literature on PET and PET/CT imaging was reviewed and summarized for prostate cancer, bladder cancer, renal cell carcinoma, and germ cell tumours. RESULTS: Depending on the radiotracer used, PET offers diagnostic information based on glucose, choline or amino acid metabolism and has also been applied to imaging tumour cell proliferation and tissue hypoxia in urological malignancies. The diagnostic performance of FDG-PET is hampered by the renal excretion of FDG and by the low metabolic activity often seen in tumours such as prostate cancer. However, new PET tracers including radiolabelled choline and acetate may offer an alternative approach. There is consistent evidence that FDG-PET provides important diagnostic information in detecting metastatic and recurrent germ cell tumours and it might offer additional information in the staging and restaging of bladder and renal cancer. CONCLUSIONS: Although PET imaging has been shown to be a clinically useful tool, its application in urological malignancies still needs to be fully determined by larger prospective trials. The introduction of novel PET radiopharmaceuticals along with the new technology of PET/CT will likely change the future role of molecular imaging in urological malignancies. |
| | |
Authors:
|
Tom Powles; Iain Murray; Cathryn Brock; Tim Oliver; Norbert Avril |
Related Documents
:
|
16304117 - Direct comparison of fdg pet and ct findings in patients with lymphoma: initial experie... 10742677 - Clinical utility of fdg-pet in detecting head and neck tumors. a comparison of diagnost... 2354407 - Staging of renal carcinoma using magnetic resonance imaging at 1.5 tesla. 19205017 - Identification of distant metastases with pet-ct in patients with suspected recurrent h... 12507267 - Hip-op: an innovative software to plan total hip replacement surgery. 9862837 - Use of magnetic resonance cholangiography in the diagnosis of choledocholithiasis: pros... |
Publication Detail:
|
Type: Journal Article; Review Date: 2007-01-23 |
Journal Detail:
|
Title: European urology Volume: 51 ISSN: 0302-2838 ISO Abbreviation: Eur. Urol. Publication Date: 2007 Jun |
Date Detail:
|
Created Date: 2007-04-30 Completed Date: 2007-07-31 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7512719 Medline TA: Eur Urol Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 1511-20; discussion 1520-1 Citation Subset: IM |
Affiliation:
|
Department of Urology, Barts and the London School of Medicine, Queen Mary, University of London, London, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Female Fluorodeoxyglucose F18 / diagnostic use* Humans Image Enhancement / methods Image Interpretation, Computer-Assisted / methods Male Neoplasm Staging Positron-Emission Tomography / methods* Prognosis Radiopharmaceuticals / diagnostic use* Sensitivity and Specificity Tomography, X-Ray Computed / methods* Urogenital Neoplasms / radiography*, radionuclide imaging* |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Development and validation of a premature ejaculation diagnostic tool.
Next Document: Resurfacing and reconstruction of the glans penis.